Daniel Petrylak
Impact in
-
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer Research top 5%
- Cancer, Lipids, and Metabolism
Papers in
-
- Prostate Cancer Treatment and Research 4
- Renal cell carcinoma treatment 1
- Prostate Cancer Diagnosis and Treatment 1
-
- Histone Deacetylase Inhibitors Research 2
- Epigenetics and DNA Methylation 1
- Co-authors
- Alan Yagoda (1 shared paper)George Wilding (3 shared papers)Susan Halabi (2 shared papers)Eric J. Small (2 shared papers)William Kevin Kelly (2 shared papers)Glenn J. Bubley (1 shared paper)Ian F. Tannock (1 shared paper)William D. Figg (1 shared paper)
- Journals
- Journal of Clinical Oncology (4 papers)JNCI Journal of the National Cancer Institute (1 paper)Cancer (1 paper)Molecular Cancer Therapeutics (1 paper)British Journal of Urology (1 paper)
- Partner nations
- United StatesUnited Kingdom
In The Last Decade
Daniel Petrylak
8 papers receiving 2.3k citations
Daniel Petrylak's Hit Papers
Peers
Comparison fields: 5 of 67
- Pulmonary and Respiratory Medicine 1.6k
- Cancer Research 320
- Oncology 492
- Radiology, Nuclear Medicine and Imaging 322
- Hematology 87
Countries citing papers authored by Daniel Petrylak
This map shows the geographic impact of Daniel Petrylak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Petrylak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Petrylak more than expected).
Fields of papers citing papers by Daniel Petrylak
This network shows the impact of papers produced by Daniel Petrylak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Petrylak. The network helps show where Daniel Petrylak may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Petrylak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group Hit paper breakdown → | 2008 | 1714 |
| 2 | 1993 | 322 | |
| 3 | 1992 | 254 | |
| 4 | 2002 | 44 | |
| 5 | 2005 | 41 | |
| 6 | 2009 | 9 | |
| 7 | 2004 | 2 | |
| 8 | A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors. | 2007 | 2 |
About Daniel Petrylak
Daniel Petrylak is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Hematology and Cancer Research, having authored 8 papers that have together received 2.4k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (4 papers), Histone Deacetylase Inhibitors Research (2 papers), Renal cell carcinoma treatment (1 paper), Prostate Cancer Diagnosis and Treatment (1 paper), Epigenetics and DNA Methylation (1 paper), Radiopharmaceutical Chemistry and Applications (1 paper), Multiple Myeloma Research and Treatments (1 paper) and Cancer, Lipids, and Metabolism (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.6k citations), Cancer Research (320 citations), Oncology (492 citations), Radiology, Nuclear Medicine and Imaging (322 citations) and Hematology (87 citations). Daniel Petrylak has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Alan Yagoda, George Wilding, Susan Halabi, Eric J. Small, William Kevin Kelly, Glenn J. Bubley, Ian F. Tannock, William D. Figg, Howard I. Scher and Michael A. Carducci. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute, Cancer, Molecular Cancer Therapeutics and British Journal of Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.